Kairos Pharma to Present Innovative Cancer Treatment Research at ASCO 2025
TL;DR
Kairos Pharma (NYSE American: KAPA) will present new data on KROS 101 at ASCO, enhancing its potential in cancer treatment.
Kairos utilizes structural biology with ENV105 to target CD105, reversing drug resistance in cancer treatments.
Kairos' research aims to improve cancer therapy by overcoming drug resistance, offering hope for better treatment outcomes.
Kairos CEO will share new findings on KROS 101 at ASCO, advancing discussions and knowledge in cancer treatment.
Found this article helpful?
Share it with your network and spread the knowledge!
Biotech company Kairos Pharma Ltd. will present critical research on its experimental cancer treatment KROS 101 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The poster, titled "Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity," will be showcased on June 2 at McCormick Place.
The presentation represents a significant opportunity for the company to share preliminary findings about KROS 101's potential mechanisms in cancer treatment. By focusing on GITR ligand agonist properties, the research aims to explore innovative approaches to enhancing the body's immune response against cancer cells.
CEO John Yu emphasized the importance of this research, noting the opportunity to advance discussions around potential new strategies for optimizing cancer treatment. The presentation could provide critical insights into how small molecule interventions might improve current therapeutic approaches.
This research builds upon Kairos Pharma's broader oncology strategy, which centers on utilizing structural biology to overcome drug resistance and immune suppression in cancer treatments. The company's approach demonstrates a sophisticated understanding of the complex challenges in developing more effective cancer therapies.
Curated from InvestorBrandNetwork (IBN)
